21st.BIO

Biotechnology Research • Gladsaxe, Capital Region of Denmark, Denmark • 51-100 Employees

Company overview

Headquarters	Sydmarken 42, Søborg, Capital Region 2860, DK
Phone number	+4532269999
Website	21st.bio
NAICS	541714
Keywords	Biotechnology, Strain Engineering, Precision Fermentation, Production Upscale
Employees	51-100
Socials

Key Contacts at 21st.BIO

Philippe Gaudin

Fermentation Director

José Arnau

Executive Director Strain Dev And Regulatory Affairs

Birgitte Andersen

Director Of Product And Optimization

Niels Banke

Senior Director Biomanufacturing

Abigail Jang

Director Of R&D California

21st.BIO Email Formats

21st.BIO uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@21st.bio), used 57.4% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@21st.bio	57.4%
{first initial}.{last name}	j.doe@21st.bio	42.6%

About 21st.BIO

21st.BIO was founded with one simple mission: to make leading industrial scale precision fermentation technology accessible to as many as possible, so companies can successfully take biotech innovations to market at a competitive price. 21st.BIO focuses on developing industrial production technology for proteins and other molecules of interest for food, nutrition, agriculture, biomaterials, and biomining industries. 21st.BIO's founders saw that too often, great bio innovation and molecules fail to translate into commercial success. The innovation is ready, the market is there, but production costs remain too high for the product to go mainstream. Industry insiders call it the 'valley of death', and that's exactly what 21st.BIO intends to bridge. Founded in 2020, 21st.BIO is headquartered in Copenhagen, Denmark, and has a world-class R&D team as well as laboratories in both Copenhagen, Denmark and Davis, California. On a mission to support bio industrial companies globally in upscaling from molecule innovation to large-scale production, 21st.BIO enables its customers to meet market demands, and thereby advance the green transition globally. Established as a fully integrated end-to-end partner, 21st.BIO supports its customers from technical assessment, strain development and optimization, production processes and upscaling, tech transfer to large scale manufacturing and regulatory services. 21st.BIO's fermentation technology is in part licensed from Novonesis, who have developed and perfected their platform over several decades.

21st.BIO revenue & valuation

Annual revenue	$5,218,855
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$16,800,000
Total funding	$97,100,000